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Poster Session II S369capacity of MultiStem (Athersys, Inc), a commercial hMAPC
product, was first evaluated in vitro in a MLC of purified mouse den-
dritic and T cells. MultiStem inhibited mouse T-cell proliferation
in a reproducible, dose dependent fashion not observed with human
dermal fibroblasts. This effect was associated with reduced T cell ac-
tivation and inflammatory cytokine secretion and robust increases in
the concentrations of PGE2 and TGFb in cell culture supernatants.
Importantly, MultiStem had no effect on the generation CTL ac-
tivity in vitro. Similar findings were observed in vivo when Multi-
Stem was delivered in the context of allo-BMT using C57BL/6
and B6D2F1 mice as donors and recipients, respectively. Tail vein
injection ofMultiStem onDay +1 (D1) and +4 (D4) resulted in sig-
nificant reductions in splenic T cell expansion and in numbers of
TNFa and IFNg-producingCD4+ andCD8+ cells at D10 compared
to untreated allo controls. These findings were associated with re-
ductions in 1) D10 serum levels of TNFa and IFNg, 2) D10 intesti-
nal and hepatic inflammation and 3) systemicGVHDasmeasured by
survival and clinical score. Suppression of systemic GVHD was ob-
served in a dose dependent manner. Biodistribution studies using
bioluminescence and cryo-imaging showed that MultiStem
tracked from the lung and into the abdominal organs (liver and
spleen) within the first 4 days after injection. When GVL effects
were tested, the administration of MultiStem resulted in superior
leukemia free survival; MultiStem treated mice had less GVHD
but effectively eradicated tumor challenge. Collectively, these data
provide critical information regarding the biodistribution and regu-
latory capacity of human MultiStem in established models of
GVHD. Mechanistic studies are ongoing, which we anticipate will
be useful in optimizing the dose and schedule of MultiStem in on-
going, first-in-human clinical trials following allogeneic BMT.448
SEVERE DENTAL CARIES IN PATIENTS WITH ORAL CHRONIC GRAFT-
VERSUS-HOST DISEASE
Castellarin, P.3, Stevenson, K.2, Treister, N.1 1Dana-Farber/Brigham
and Women’s Cancer Center, Boston, MA; 2Dana-Farber Cancer Insti-
tute, Boston, MA; 3Universtity of Trieste, Trieste, Italy
Objective:The oral cavity is one of themost frequently affected sites
by cGVHD following allogeneic hematopoietic cell transplantation
(alloHCT), and can be a significant source of patient morbidity due
to bothmucosal and salivary gland involvement. The development of
dental decay is a potentially devastating oral complication that has
only rarely been reported in the transplantation literature. The pur-
pose of this study was to comprehensively characterize a cohort of
patients with cGVHD that subsequently developed extensive dental
caries.
Methods: A retrospective case-record review was conducted for pa-
tients who had undergone alloHCT at Dana-Farber/Brigham and
Women’s Cancer Center between 1990 and 2010 and developed
cGVHD-associated rampant dental decay. All patients underwent
dental evaluations before and after alloHCT that consisted of
a soft and hard tissue examination and dental radiographs. Caries di-
agnosed from the pre-alloHCT evaluation were treated definitively
such that all patients were considered free of caries at the time of ad-
mission for HCT.
Results: A total of 21 patients were identified with a median time of
cGVHDonset of 5.4months (range 2.2-18.5) post-alloHCT. All pa-
tients were diagnosed with oral cGVHD, with 90% demonstrating
mucosal involvement, and 95% with salivary gland involvement.
Post-alloHCT dental evaluation was performed at a median of 22
months (range 4-81) after alloHCT. when ten patients were diag-
nosed with gross caries and eight patients presented four or more af-
fected teeth. Cervical and interproximal patterns of dental caries
were frequently diagnosed. The proportion of patients with gross,
one surface, and greater than one surface caries, categorized as 0,
1-3, or $4, were significantly higher post-alloHCT compared to
pre-alloHCT with at least 50% of patients experiencing an increase.
Conclusions: Patients with oral cGVHD, who were free of caries at
the time of transplantation, developed extensive areas of cervical de-
cay in amedian time of less than two years post-alloHCT. This is the
first comprehensive characterization of this severe late complication
of alloHCT and oral cGVHD. Greater awareness on the part oftransplant oncologists and dentists as well asmore aggressive preven-
tive measures are warranted, as well as prospective studies to better
elucidate the incidence of this complication, identify risk factors,
and evaluate the effectiveness of preventive interventions.449
IN VIVO REFLECTANCE CONFOCAL MICROSCOPY IN THE EARLY DIAGNO-
SIS OF ACUTE CUTANEOUS GRAFT-VERSUS-HOST DISEASE: A PILOT
STUDY
Corbin, J.M., MacDonald, A., Purdy, K.S., Webb, A., Pasternak, S.,
Couban, S., Langley, R.G. Dalhousie University, Halifax, NS, Canada
Background: Graft-versus-host disease (GVHD) is a common and
potentially life-threatening complication of allogeneic hematopoi-
etic stem cell transplantation. The diagnosis of cutaneous GVHD
can be challenging, as it is based on clinical presentation, which often
simulates other processes. Early recognition and treatment are es-
sential to reduce the associated morbidity and mortality. Reflectance
confocal microscopy (RCM) is a high-resolution, noninvasive tech-
nique that may facilitate a timely diagnosis and prompt institution
of treatment.
Objective: We sought to describe the features of acute cutaneous
GVHD under RCM and to correlate these with the histopathologi-
cal findings.
Methods: Patients were recruited prospectively to undergo clinical
and RCM examination. A total of 19 patients were enrolled, five of
whom developed acute cutaneous GVHD following an allogeneic
hematopoietic stem cell transplant. RCM images from these five
cases were examined and the key confocal features were compared
to histopathological findings.
Results:OnRCMexamination, features of acute cutaneousGVHD,
such as apoptotic keratinocytes, inflammatory cell infiltration and in-
terface dermatitis, were identified and were shown to correlate well
with histopathological findings.
Limitations: The open-label, unblinded nature of this study allows
for potential observer bias and the small sample size may not reflect
the findings in a larger population. The sensitivity and specificity of
RCM in this population remain to be determined.
Conclusion: The findings support further examination of the use of
RCM in the rapid, bedside diagnosis of acute cutaneous GVHD.450
SIGNIFICANT ADVERSE EFFECTS ASSOCIATED WITH SIROLIMUS/TACRO-
LIMUS GVHD PROPHYLAXIS REGIMEN (SIRO-tac) IN ALLOGENEIC HEM-
ATOPOEITIC STEM CELL TRANSPLANT (alloHSCT) PATIENTS (pts): A
SINGLE INSTITUTION EXPERIENCE
Nathan, S., Maciejewski, J.J., Rich, E.S., Gregory, S.A., Schultz, K.,
Fung, H.C. Rush University Medical Center, Chicago, IL
Background: On account of the increased transplant related mor-
bidity and mortality with the use of methotrexate (MTX) based im-
munosuppressive therapy we adopted a new policy in GVHD
prophylaxis using a combination of tacrolimus and sirolimus abort-
ing the use ofMTX.We report the adverse effects that were noted in
our patients who underwent a related or un-related AlloHSCT
transplantation.
Patients and Methods: Data from 46 consecutive AlloHSCT pts
over a 2 year period were reviewed. 39 pts who received siro-tac
with or without ATG were identified. Demographics, indication
for transplantation, type of donor, conditioning regimen (CR),
GVHD prophylaxis associated complications were identified and
collected.
Results: 46 pts underwent an alloHSCT at our institution from
2009-11. 39 (84.78%) pts (average age 44 yrs, range 20-65 yrs) re-
ceived Siro-tac with or without ATG and all without MTX. 21
(53.84%) pts were male and 18 (46.15%) pts female. Indications
for transplant included relapsed non-Hodgkin lymphoma, Hodgkin
lymphoma, acute myelogenous leukemia, acute and chronic lympho-
cytic leukemia, myelodysplastic syndrome and myelofibrosis. 15
(46.15%) pts received a myeloablative CR. 14 pts had an unrelated
S370 Poster Session II(35.9%) and 8 (20.51%) pts had a HLAmismatched donor. Therapy
associated complications identified included hyperacute GVHD
(13pts [33.3%]), acute renal failure (13 pts [33.3%]), hemolysis (14
pts [35.9%]), neuro-toxicity (7 pts [17.95%]), cytopenias (10 pts
[25.6%]), dyslipidemia (6 pts [15.4%]) and skin changes (2 pts
[5.13%]). 15 pts (38.5%) had GrIII-IV GVHD. 12 pts (30.8%)
died of who 3 (25%) were directly related to the siro-tac associated
toxicity.
Conclusions:We conclude that the sirolimus-tacrolimus combina-
tion GVHD prophylaxis regimen, is associated with considerable
toxicities that contribute to the transplant associated morbidity
and mortality in the allogeneic hematopoietic stem cell transplanta-
tion setting, not attributable to the conditioning regimen. Therefore
this regimen should be used cautiously outside of a clinical trial.
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RESTING REGULATORY T LYMPHOCYTES: A BIOMARKER FOR CHRONIC
GVHD
Parkman, R., Masinsin, B., Mahadeo, K.M., Kapoor, N., Abdel-
Azim, H.M., Shah, A.J. Children’s Hospital Los Angeles, Los Angeles, CA
T cell depletion and peri-transplant serotherapy have reduced the
incidence and severity of acute graft versus host disease (GVHD);
however, chronic GVHD continues to be a major clinical limitation
to the increased use of hematopoietic stem cell transplantation
(HSCT). Deficiencies in naturally occurring regulatory T lympho-
cytes (Treg) have been hypothesized to contribute to chronic
GVHD. The evaluation of the role of Treg lymphocytes in the path-
ogenesis of chronic GVHD have been limited by a lack of well-de-
fined immunophenotypic characterization of Treg lymphocytes.
Most previous evaluations of Treg lymphocytes inHSCT recipients,
which used either CD25 and/or FoxP3 expression, were confounded
by the fact that activated conventional T lymphocytes (Tcon) ex-
pressed CD25 and FoxP3. We have performed a cross-sectional
analysis of pediatric HSCT recipients using theMiyara classification
of Treg lymphocytes. (Immunity 30:899, 2009) The Miyara classifi-
cation can distinguishes between Treg lymphocytes, both resting
and activated, and activated Tcon lymphocytes, permitting a more
accurate assessment of Treg in the HSCT setting. Pediatric
HSCT recipients more than 1 year post-HSCT were evaluated for
their resting (r) and activated (a) Treg lymphocytes and their r/a ratio
determined. (Table 1)
Table 1. Resting and Activated Treg Lymphocytes in HSCT
Recipients
rTreg aTregPatient r/a ratio
(% of total CD4
T lymphocytes x 1021)Allogeneic-
No hx of acute/chronic GVHD 17.3 6.2 4.7
Active chronic GVHD 6.4 1.8 3.5
Hx of chronic GVHD 14.0 6.8 3.2
Autologous 11.3 5.2 2.2
Normal Individuals 19.3 3.6 3.9Allogeneic HSCT recipients with no history of either acute or
chronic GVHD did not differ from normal individuals. Neither
did allogeneic recipients with only a history of acute GVHD nor
the recipients of autologousHSCT. Allogeneic recipients with active
chronic GVHD had reductions in both the percentage of resting
Treg lymphocytes (p 5 .02 compared to normal or recipients with
neither acute nor chronic GVHD) and of activated Treg lympho-
cytes (p 5 .002 compared to recipients without acute or chronic
GVHD and p5 .0008 compared to normals). Allogeneic recipients,
who have had the clinical resolution of their chronic GVHD, did not
differ from normal individuals. The clinical resolution of chronic
GVHD is associated with a normalization of both resting and acti-
vated Treg lymphocytes. The longitudinal evaluation of resting
Treg levels may aid in the management of chronic GVHD patients
and may predict when clinical improvement occurs.452
BORTEZOMIB FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST
DISEASE (GVHD)
Wagner, J.L., Mookerjee, B., Filicko-O’Hara, J.E., Grosso, D.A.,
Flomenberg, N. Thomas Jefferson University Kimmel Cancer Center,
Philadelphia, PA
Steroid refractory GVHD remains a significant problem after
allogeneic HSCT with a mortality rate exceeding 90% in some
series and no standard for salvage treatment. Murine data suggest
bortezomib inhibits acute GVHD, but preserves graft-versus-tu-
mor effect. We sought to test whether the same activity could
be demonstrated in a clinical setting. Patients were eligible for
the trial if they had clinical or histological evidence of acute
GVHD and had been treated with 2mg/kg/day of methylprednis-
olone and had 1) either a minimum of 3 days of corticosteroids
with progressive disease or 2) a minimum of 7 days without a re-
sponse or 3) had progression when steroids were tapered to less
than 2mg/kg/day of methylprednisolone. Bortezomib was given
at a dose of 1.3mg/m2 administered as a bolus intravenous injec-
tion twice weekly for 2 weeks (days 1, 4, 8, 11) followed by a 10
day rest period constituting one 21 day treatment cycle. A com-
plete response (CR) was defined as no clinical or laboratory signs
of acute GVHD in all organs, and a partial response (PR) re-
quired at least a 1 grade reduction in overall GVHD scoring
in at least 1 organ system without worsening in others. Response
was determined on day 21 after the first cycle and every 3 weeks
until 3 months after the last cycle or death whichever came first.
After the 1st cycle, patients achieving CR or PR were treated
with additional cycles until they had a dose limiting toxicity or
a complete response, and patients without response were taken
off study and considered treatment failure. Three of 11 patients
treated were not evaluable for efficacy; 1 withdrew from the
study after less than 1 cycle without signs of toxicity, 1 died 1
week after receiving the 1st cycle of septic shock, and the 3rd pa-
tient developed a concomitant viral infection that could not be
distinguished from possible concomitant GVHD. Of the 8 evalu-
able patients 4 had no response and 4 had at least a partial re-
sponse. In the 4 patients with responses 2 were complete
responses and 2 were partial. Ten of the 11 patients have died,
2 of progressive disease, 6 of infection, 1 of hemorrhage and 1
of pulmonary toxicity. Whether bortezomib contributed to any
of these deaths was unclear. One of the partial responders was
taken off the study for peripheral neuropathy and is still alive
4.5 years later. In this small study bortezomib demonstrated
some activity in steroid refractory acute GVHD with some neu-
rotoxicity.453
LATENT CMV AND THE CD4+ T CELL TRANSCRIPTION PROGRAM IN PA-
TIENTS WITH CHRONIC GVHD
Astigarraga, C.C.1, Tabellini, L.1, Pergam, S.1, Bumgarner, T.1,
Fan, W.1, Grogan, B.1, Storer, B.1, Boeckh, M.1,2, Zaho, L.P.1,
Hansen, J.A.1,2 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Washington, Seattle, WA
Latent CMV infection is known to have a life long effect on
the distribution of T cell subsets, but little is known about the
impact on cell function. We performed a gene expression analysis
in purified CD4+ T cells from 68 hematopoietic cell transplant
(HCT) recipients (median age 48; range 20-65) studied on aver-
age 5 years after HCT (median 4.75; range 1-20 years). The
study population included 38 patients with active chronic
GVHD (cGVHD) and 30 tolerant (TOL) patients. Tolerance
was defined by absence of signs, symptoms of cGVHD and im-
munosuppressive therapy (IST) for 3 months. Gene expression
was measured on Illumina bead arrays. CMV status was defined
by pre-transplant recipient CMV serology (by ELISA). There
was no recorded evidence of CMV reactivation at the time of
study. Nine of 93 candidate genes associated with immune func-
tion and inflammation were found to be associated CMV seros-
tatus in cGVHD patients at a significance threshold of p\0.05,
but only four genes (ITK; CD86; PLCG1; PIK3CB) were
